Correlation Between Inhibikase Therapeutics and Day One

Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Day One at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Day One into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibikase Therapeutics and Day One Biopharmaceuticals, you can compare the effects of market volatilities on Inhibikase Therapeutics and Day One and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Day One. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Day One.

Diversification Opportunities for Inhibikase Therapeutics and Day One

-0.42

Correlation Coefficient

Inhibikase Therapeutics  Day One

Very good diversification

The 3 months correlation between Inhibikase and Day is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Day One Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Day One Biopharmaceu and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Day One. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Day One Biopharmaceu has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Day One go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and Day One

Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 3.66 times more return on investment than Day One. However, Inhibikase Therapeutics is 3.66 times more volatile than Day One Biopharmaceuticals. It trades about 0.03 of its potential returns per unit of risk. Day One Biopharmaceuticals is currently generating about -0.28 per unit of risk. If you would invest  321.00  in Inhibikase Therapeutics on October 10, 2024 and sell it today you would earn a total of  0.00  from holding Inhibikase Therapeutics or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	95.24%
Values	Daily Returns

Inhibikase Therapeutics  vs.  Day One Biopharmaceuticals

Inhibikase Therapeutics

Risk-Adjusted Performance

18 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Day One Biopharmaceu

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Inhibikase Therapeutics and Day One

The main advantage of trading using opposite Inhibikase Therapeutics and Day One positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Day One can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will offset losses from the drop in Day One's long position.

The idea behind Inhibikase Therapeutics and Day One Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.